Candida glabrata has thoroughly adapted to successfully colonize human mucosal membranes and survive in vivo pressures. prior to and during antifungal treatment. Out of all the medically relevant
Candida species,
C. glabrata has emerged as a leading cause of azole, echinocandin, and multidrug (MDR: azole + echinocandin) adaptive resistance. Neither mechanism of resistance is intrinsic to
C. glabrata, since stable genetic resistance depends on mutation of drug target genes,
FKS1 and
FKS2 (echinocandin resistance), and a transcription factor,
PDR1, which controls expression of major drug transporters, such as
CDR1 (azole resistance). However, another hallmark of
C. glabrata is the ability to withstand drug pressure both in vitro and in vivo prior to stable “genetic escape”. Additionally, these resistance events can arise within individual patients, which underscores the importance of understanding how this fungus is adapting to its environment and to drug exposure in vivo. Here, we explore the evolution of echinocandin resistance as a multistep model that includes general cell stress, drug adaptation (tolerance), and genetic escape. The extensive genetic diversity reported in
C. glabrata is highlighted.
View Full-Text
►▼
Show Figures
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited